PharmaEssentia Corporation (TPE:6446)
Taiwan
· Delayed Price · Currency is TWD 508.00
+11.00 (2.21%)
May 14, 2025, 1:30 PM CST
PharmaEssentia Revenue
PharmaEssentia had revenue of 3.26B TWD in the quarter ending March 31, 2025, with 97.00% growth. This brings the company's revenue in the last twelve months to 11.34B, up 93.12% year-over-year. In the year 2024, PharmaEssentia had annual revenue of 9.73B with 90.67% growth.
Revenue (ttm)
11.34B
Revenue Growth
+93.12%
P/S Ratio
14.92
Revenue / Employee
86.55M
Employees
131
Market Cap
169.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.73B | 4.63B | 90.67% |
| Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
| Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
| Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
| Dec 31, 2020 | 557.26M | 251.57M | 82.29% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 40.47M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 19.12B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.33M |
| Lumosa Therapeutics | 43.59M |
| Pegavision | 6.69B |
| Center Laboratories | 1.63B |
PharmaEssentia News
- 3 months ago - ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Benzinga